27 Leukemia Clinical Trials in Dallas, PA (2026)

Q: How do I join a clinical trial in Dallas?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you.

Recruiting Leukemia Studies in Dallas

NCT06698315Recruiting

Evidence-based Approach to Reduce Falls in Adult Patients

The project aims to promote patient safety and quality care by reducing preventable falls and falls with injuries using an evidence-based solution....

Dallas, PA1,000 participantsMethodist Health System

View Study Details

NCT05208762Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect i...

Dallas, PA714 participantsSeagen, a wholly owned subsidiary of Pfizer

View Study Details

NCT07349537Recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or...

Dallas, PA574 participantsRevolution Medicines, Inc.

View Study Details

NCT05736029Recruiting

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between spec...

Dallas, PA350 participantsOncoHost Ltd.

View Study Details

NCT04877522Recruiting

Asciminib Roll-over Study

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment...

Dallas, PA347 participantsNovartis Pharmaceuticals

View Study Details

NCT06406114Recruiting

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of...

Dallas, PA300 participantsMassachusetts General Hospital

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

Dallas, PA290 participantsCrescent Biopharma, Inc.

View Study Details

NCT07612176Recruiting

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion p...

Dallas, PA155 participantsNEOK Bio, Inc.

View Study Details

NCT07612189Recruiting

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion po...

Dallas, PA155 participantsNEOK Bio, Inc.

View Study Details

NCT06515990Recruiting

A Study of DM005 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors. DM005 is an experimental drug which is not approved by...

Dallas, PA136 participantsDoma Biopharmaceutical（Suzhou）Co., Ltd.

View Study Details

NCT05401097Recruiting

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

This phase II study compares the order of treatment with ivosidenib or enasidenib and azacitidine plus venetoclax in treating older patients with acute myeloid leukemia with genetic changes in the IDH...

Dallas, PA125 participantsAlice Mims

View Study Details

NCT07271667Recruiting

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL....

Dallas, PA108 participantsCuris, Inc.

View Study Details

NCT06794229Recruiting

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

All subjects will receive zanzalintinib 100mg orally (PO) once daily plus nivolumab standard of care dosing (i.e., 240mg IV every 2 weeks or 480mg IV every 4 weeks) for a total of 12 weeks, followed b...

Dallas, PA69 participantsQian Qin

View Study Details

NCT07015996Recruiting

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

The proposed study is a proof-of-concept Phase 2, double-blind, randomized placebo-controlled clinical trial evaluating the safety and efficacy of tezepelumab and peanut Oral Immunotherapy (OIT) for t...

Dallas, PA62 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT05703971Recruiting

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is...

Dallas, PA62 participantsGenprex, Inc.

View Study Details

NCT06456541Recruiting

Infant Formula in Infants and Children With Cow's Milk Allergy

This is a multi-center, randomized, double-blinded, placebo-controlled food challenge to be conducted in infants and children with confirmed IgE-mediated cow's milk allergy (CMA), followed by a 7-day ...

Dallas, PA61 participantsAbbott Nutrition

View Study Details

NCT03874052Recruiting

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax and compares the effect of ruxolitinib in combination with venetoclax to venetoclax and aza...

Dallas, PA51 participantsJennifer Saultz

View Study Details

NCT07139990Recruiting

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses....

Dallas, PA45 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT07140016Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some ...

Dallas, PA40 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT06634394Recruiting

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML....

Dallas, PA39 participantsAptevo Therapeutics

View Study Details

NCT07276789Recruiting

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intrave...

Dallas, PA35 participantsIntegro Theranostics

View Study Details

NCT04659616Recruiting

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

This phase I trial identifies the best dose and clinical benefit of giving pemigatinib following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib se...

Dallas, PA32 participantsOHSU Knight Cancer Institute

View Study Details

NCT06943534Recruiting

Omalizumab Weight-Based Dosing Efficacy Trial

This research is being conducted to assess the safety and effectiveness of increased dosing of Omalizumab for food allergies....

Dallas, PA30 participantsMassachusetts General Hospital

View Study Details

NCT06415487Recruiting

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expre...

Dallas, PA30 participantsAcepodia Biotech, Inc.

View Study Details

NCT06177067Recruiting

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid...

Dallas, PA24 participantsSt. Jude Children's Research Hospital

View Study Details

NCT03571321Recruiting

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leuke...

Dallas, PA15 participantsUniversity of Chicago

View Study Details

NCT05452720Recruiting

MASA Valve Early Feasibility Study

The MASA Valve Early Feasibility Study (MVEFS) multi-site interventional clinical trial within the United States of America with each center following a common protocol.The objective of the trial is t...

Dallas, PA10 participantsPECA Labs

View Study Details

About Leukemia Clinical Trials in Dallas

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 27 leukemia clinical trials recruiting participants in Dallas, PA. These studies are seeking a combined 4,859 participants. Research is being sponsored by Methodist Health System, Seagen, a wholly owned subsidiary of Pfizer, Revolution Medicines, Inc. and 22 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Dallas — FAQ

Are there leukemia clinical trials in Dallas?

Yes, there are 27 leukemia clinical trials currently recruiting in Dallas, PA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Dallas?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you about next steps.

Are clinical trials in Dallas free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Dallas studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 27 active trials in Dallas are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 13, 2026 from ClinicalTrials.gov